We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Haploidentical Stem Cell Transplantation With CD3/CD19 Depletion and Reduced Intensity Conditioning in Patients With Acute Leukemia (CD3/CD19 Haplo)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00961142
Recruitment Status : Unknown
Verified December 2014 by Prof. Dr. med. Wolfgang Bethge, University Hospital Tuebingen.
Recruitment status was:  Recruiting
First Posted : August 18, 2009
Last Update Posted : December 4, 2014
Information provided by (Responsible Party):
Prof. Dr. med. Wolfgang Bethge, University Hospital Tuebingen

Brief Summary:
Feasibility and toxicity of haploidentical allogeneic HCT after a reduced intensity conditioning regimen with CD3/CD19 depleted grafts. This study enrolls patients with acute leukemia in complete remission with an indication for allogeneic HCT but without a suitable HLA-identical donor

Condition or disease Intervention/treatment Phase
Acute Myeloid Leukemia Acute Lymphoblastic Leukemia Drug: Fludarabine, Thiotepa, Melphalan, Thymoglobuline (ATG) Phase 2

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Multicenter Phase II Study of Haploidentical Hematopoietic Cell Transplantation With CD3/CD19 Depleted Grafts After a Reduced Intensity Conditioning Regimen for Adult Patients With Acute Leukemia
Study Start Date : June 2009
Estimated Primary Completion Date : June 2015
Estimated Study Completion Date : June 2016

Intervention Details:
    Drug: Fludarabine, Thiotepa, Melphalan, Thymoglobuline (ATG)
    Conditioning with Fludarabine 30 mg/m2/24h day-8 to -4, Thiotepa 2x5 mg/kg day -3, Melphalan 60 mg/m2 day -2 to -1 and Thymoglobuline (ATG)1.5mg/kg/day day -9 to -6. PBSC depleted of CD3 and CD19 cells by immunomagnetic depletion on CliniMACS.

Primary Outcome Measures :
  1. Evaluation of treatment related mortality after haploidentical HCT [ Time Frame: 1 year after HCT ]
    Cumulative Incidence of treatment related mortality

Secondary Outcome Measures :
  1. overall survival [ Time Frame: 1, 2 and 5 years after inclusion ]
    by Kaplan-Meier

  2. Evaluate Engraftment [ Time Frame: One year after HCT ]
  3. Evaluate Toxicity [ Time Frame: One year after HCT ]
  4. Evaluate Disease Free Survival [ Time Frame: 1, 2 and 5 years after inclusion ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with either ALL or AML in CR with an indication for allogeneic HCT according to the following criteria:
  • AML: high risk patients with one or more of the following risk factors:

    • FLT-3 mutation
    • Complex cytogenetics
    • abn(3q), -5/5q-, -7/7q-, abn(12p), abn(17p)
    • Late CR > induction I
    • Age >60
    • Patients in 2.CR
    • Secondary AML
    • Relapse after a preceding allogeneic HCT from an HLA-identical donor
  • ALL: high risk patients with one or more of the following risk factors:

    • Pro-B-ALL
    • Initial WBC >30.000/µL
    • CR after day 46 after Induction II
    • Complex cytogenetics, t(9,22), t(4,11)
    • Early or mature T-ALL
    • Initially refractory patients with late CR
    • Rising MRD level
    • Patients in 2. CR
    • Relapse after a preceding allogeneic HCT from an HLA-identical donor
    • No HLA-identical donor (not more than 1 antigen mismatch (9/10-Match) or more than 2 allelic mismatches by high-resolution typing). Critical cases should be discussed with the PI.
    • Age <=65, >=18 years
    • Karnofsky Index >60%

Exclusion Criteria:

  • Patients with >5% blasts in BM at the time of transplantation
  • Less than 3 months after preceding HCT
  • CNS involvement with disease
  • History of neurologic impairment such as: seizures, severe peripheral neuropathy, signs of leukoencephalopathy, CNS infection, multiple intrathecal chemotherapies, CNS irradiation. In case of heavy pretreatment with irradiation or intrathecal chemotherapy pretransplant CNS MRI and neurological consultation are mandatory
  • Fungal infections with radiological progression after receipt of amphotericin B or active triazole for greater than 1 month.
  • Liver function abnormalities with bilirubin >2 mg/dL and elevation of transaminases higher 2x upper limit of normal.
  • Chronic active viral hepatitis
  • Ejection fraction <40 % on echocardiography
  • Patients with > grade II hypertension by CTC criteria
  • Creatinine clearance <50 ml/min
  • Respiratory failure necessitating supplemental oxygen or DLCO <30%
  • Allergy against murine antibodies
  • HIV-Infection
  • Female patients who are pregnant or breast feeding, or adults of reproductive potential not employing an effective method of birth control during study treatment and for at least 12 months thereafter. (Women of childbearing potential must have a negative serum pregnancy test at study entry)
  • Concurrent severe and/or uncontrolled medical disease (e.g. uncontrolled diabetes, congestive heart failure, myocardial infarction within 6 months prior to the study, unstable and uncontrolled hypertension, chronic renal disease, or active uncontrolled infection) which could compromise participation in the study
  • Patients with a history of psychiatric illness or condition which could interfere with their ability to understand the requirements of the study (this includes alcoholism/drug addiction)
  • Patients unwilling or unable to comply with the protocol
  • Unable to give informed consent
  • Enrollment in an other trial interfering with the endpoints of this study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00961142

Contact: Wolfgang A Bethge, MD +49-7071-29 ext 83176 wolfgang.bethge@med.uni-tuebingen.de
Contact: Christoph Faul, MD +49-7071-29 ext 84087 christoph.faul@med.uni-tuebingen.de

University of Dresden Medical Center Recruiting
Dresden, Germany, D-01307
Contact: Martin Bornhaeuser, MD    49-351-458-4186    bornhaeuser@mk1.med.tu-dresden.de   
Principal Investigator: Martin Bornhäuser, MD         
Center for Marrow Transplantation, University of Essen Recruiting
Essen, Germany, 45122
Contact: Dietrich Beelen, MD         
Contact    49-201-723 ext 3136    Dietrich.Beelen@uk-essen.de   
Principal Investigator: Dietrich Beelen, MD         
Medical Center University of Halle Recruiting
Halle, Germany, 06120
Contact: Lutz Müller, MD       lutz.mueller@uk-halle.de   
Principal Investigator: Lutz Müller, MD         
Medical Center University of Hamburg Recruiting
Hamburg, Germany, 20246
Contact: Nikolaus Kroeger, MD       nkroeger@uke.uni-hamburg.de   
Principal Investigator: Nikolaus Kröger, MD         
Medical Center University of Muenster Recruiting
Muenster, Germany, 48149
Contact: Matthias Stelljes, MD         
Principal Investigator: Matthias Stelljes, MD         
South West German Cancer Center, University of Tuebingen Medical Center Recruiting
Tuebingen, Germany, 72076
Contact: Wolfgang A Bethge, MD    49-7071-298-3176    wolfgang.bethge@med.uni-tuebingen.de   
Contact: Christoph Faul, MD    49-7071-298-4087    christoph.faul@med.uni-tuebingen.de   
Principal Investigator: Wolfgang A Bethge, MD         
Deutsche Klinik für Diagnostik Recruiting
Wiesbaden, Germany, 65191
Contact: Gernot Stuhler, MD       kmt@dkd-wiesbaden.de   
Contact: Michael Schleuning, MD       kmt@dkd-wiesbaden.de   
Principal Investigator: Gernot Stuhler, MD         
University of Wuerzburg Medical Center Recruiting
Wuerzburg, Germany, D-97070
Contact: Hermann Einsele, MD    49-931-2017-0012      
Principal Investigator: Hermann Einsele, MD         
Sponsors and Collaborators
University Hospital Tuebingen
Principal Investigator: Wolfgang A. Bethge, MD Medical Center University Hospital Tuebingen

Additional Information:
Responsible Party: Prof. Dr. med. Wolfgang Bethge, Prof. Dr., University Hospital Tuebingen
ClinicalTrials.gov Identifier: NCT00961142     History of Changes
Other Study ID Numbers: EudraCT 2007-006016-33
First Posted: August 18, 2009    Key Record Dates
Last Update Posted: December 4, 2014
Last Verified: December 2014

Keywords provided by Prof. Dr. med. Wolfgang Bethge, University Hospital Tuebingen:
Haploidentical Transplantation
CD3/CD19 Depletion
Reduced Intensity Conditioning

Additional relevant MeSH terms:
Leukemia, Myeloid, Acute
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia, Lymphoid
Neoplasms by Histologic Type
Leukemia, Myeloid
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Fludarabine phosphate
Antineoplastic Agents
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antineoplastic Agents, Alkylating
Alkylating Agents
Myeloablative Agonists